Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature review

Author： Bellati Filippo   Napoletano Chiara   Ruscito Ilary   Pastore Maria   Pernice Milena   Antonilli Morena   Nuti Marianna   Benedetti Panici Pierluigi  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.28, Iss.6, 2010-12, pp. : 887-894

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab costly for ovarian cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 624, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Bevacizumab in Ovarian Cancer: Unanswered Questions

By Muggia Franco  

Drugs, Vol. 72, Iss. 7, 2012-05 ,pp. : 931-936

Adis International

Access to resources Recommend Favorite

Survival Benefit of Adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the Different Time-points of Treatment of Ovarian Cancer: Review of Evidence

By  

Current Pharmaceutical Design, Vol. 18, Iss. 25, 2012-07 ,pp. : 3793-3803

Bentham Science Publishers

Access to resources Recommend Favorite

Counterpoint: Intraperitoneal Chemotherapy: An Investigational Treatment in Ovarian Cancer

By Ozols Robert F.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 6, 2004-11 ,pp. : 555-560

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Point: Intraperitoneal Chemotherapy in the Management of Ovarian Cancer

By Markman Maurie  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 2, Iss. 6, 2004-11 ,pp. : 549-554

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite